Sajja Venkatesh on the Results of CREST-2 Trial
Sajja Venkatesh, Interventional Neurologist, FNB-NeuroVascular Intervention at Apollo Hospitals, shared on LinkedIn:
”CREST-2 Trial: Carotid artery stenting (CAS) vs Carotid Endarterectomy (CEA) for asymptomatic high-grade carotid stenosis (≥70%) who have not had recent stroke symptoms,
- Addition of CAS resulted in a reduced risk of a composite of perioperative stroke, death, or ipsilateral stroke within a 4 year timeframe, surpassing the outcomes achieved through intensive medical management alone.
- Conversely, CEA did not demonstrate a statistically significant advantage.
Primary Outcome:
– Stenting Trial: The 4-year incidence of stroke or death was significantly lower in the stenting group (2.8%) compared to the medical-therapy group (6.0%), with an absolute risk reduction of 3.2 percentage points (P=0.02).
– Endarterectomy Trial: No significant difference was observed between the endarterectomy group (3.7%) and the medical-therapy group (5.3%) (P=0.24).”
Read the full article here.
Article: Medical Management and Revascularization for Asymptomatic Carotid Stenosis
Authors: CREST-2 Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 14:30Bharat Moyal: The New KDIGO 2026 Approach to Anemia in CKD
-
Aug 11, 2026, 14:16Rayan Ahmed: Master Blood Films and Pathology Online
-
Aug 11, 2026, 13:53Steven Lubega: Why Are Healthy Newborns Born Poorly Equipped To Stop Bleeding?
-
Aug 11, 2026, 13:47Why Stroke Risk Changes During Pregnancy – International Journal of Stroke
-
Aug 11, 2026, 13:43Moyahabo Julius Rampya: Shaping the Future of Stroke Care in Africa
-
Aug 11, 2026, 13:34Brett Hoover: Plaque Burden May Be Key to Predicting MACE Risk
-
Aug 11, 2026, 11:47Rucha Patil: Strengthening Evidence-Based Haemophilia Care Across India
-
Aug 11, 2026, 11:38Maria Hadjidemetriou: The Patient Perspective in Thalassemia Care
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD